Trial
NCT00386399
Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene
Phase IIWITHDRAWNEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
Van Andel Research Institute
Condition
Pancreatic Cancer
Intervention
Mitomycin-C
Why stopped
All consented subjects tested negative for the BRCA2 mutation, therefore, did not meet criteria to start the study, resulting in withdrawal by PI
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-07-12